REMSleep Holdings, Inc. is preparing to sign a significant distribution agreement that will bring its DeltaWave sleep apnea treatment device to markets across the United States. The company anticipates resolving previous inventory challenges, with product availability expected by April 25, 2025.
The potential nationwide distribution represents a strategic milestone for REMSleep, a medical device manufacturer specializing in obstructive sleep apnea treatments. While the specific distributor remains undisclosed, the agreement signals potential growth for the company's respiratory care product line.
Recent inventory delays that previously hindered product availability have been addressed, according to company statements. REMSleep executives express confidence that these challenges have been resolved and do not anticipate further disruptions to their distribution strategy.
The DeltaWave device's potential nationwide release could provide significant benefits for sleep apnea patients. With the REMSleep team possessing over 30 years of collective experience in CPAP therapy, the company aims to improve patient treatment and compliance in managing respiratory conditions.
This distribution agreement represents a critical step in REMSleep's strategy to expand access to innovative sleep apnea treatment technologies, potentially offering new options for patients struggling with respiratory health challenges.
